Natco Pharma Limited — Updates, 24-07-2025: Press Release

NATCO Pharma's API manufacturing plant in Mekaguda, Hyderabad, has successfully closed its recent U.S. FDA inspection. The company received one Form-483 observation, classified as "Voluntary Action Indicated" (VAI), signifying no immediate regulatory action by the FDA. The facility has now received its Establishment Inspection Report (EIR), formally concluding the inspection. This positive development provides clarity and operational stability for the plant, critical for its continued supply to the US market.